Pegfilgrastim biosimilar - Hospira

Drug Profile

Pegfilgrastim biosimilar - Hospira

Alternative Names: HSP-130; PF-06881894

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hospira
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Febrile neutropenia
  • Phase I Neutropenia

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Neutropenia in United Kingdom (SC, Injection)
  • 09 Sep 2017 Pfizer plans a phase I trial in Healthy volunteers (NCT03273842)
  • 01 Jun 2016 Hospira completes a phase I trial in Neutropenia (In volunteers) in Australia (NCT02629289)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top